56 results about "Atrophic mucosa" patented technology

The invention relates to the technical field of life science, in particular to a method for constructing an atrophic gastritis-based SPEM lesion model, which comprises the following steps: S1, constructing an Slc7a11 conditional knockout mouse strain: carrying out cage hybridization on an Slc7a11 flox / flox mouse and an ATP4b-Cre transgenic mouse, and knocking out a gastric wall cell specific Slc7a11 gene; s2, carrying out genotyping identification; the identification method based on the atrophic gastritis SPEM lesion model and the construction method based on the atrophic gastritis SPEM lesion model comprise the following steps: S1, pathological model verification: taking a mouse gastric mucosa tissue slice, quantitatively analyzing the proportion of an SPEM region by adopting an immunofluorescence double-standard technology, and confirming Slc7a11 knockout induced SPEM pathological characteristics in combination with the existence of SPEM in the gastric mucosa; and S2, long-term pathology evolution monitoring. Through gastric wall cell specific Slc7a11 gene knockout and multiple PCR identification technologies, the initial response SPEM state after gastric mucosa damage is successfully simulated, and the kit is used for researching atrophic gastritis pathological mechanisms and evaluating drug intervention.

The invention discloses a pharmaceutical composition for preventing and treating chronic atrophic gastritis. The pharmaceutical composition is prepared from the following raw materials in the following weight ratio: 14-18 parts of peach kernel, 10-14 parts of Chuanxiong rhizome, 8-12 parts of Panax notoginseng, 6-10 parts of safflower, 20-28 parts of kelp, 10-14 parts of selfheal, 15-25 parts of codonopsis pilosula, 10-14 parts of atractylodes macrocephala, 12-16 parts of fructus aurantii, 8-12 parts of amomum villosum, 12-16 parts of bupleurum, 10-18 parts of citron, and 5-10 parts of fucoidan. The pharmaceutical composition is used to treat chronic atrophic gastritis of gastric collateral blood stasis type by promoting blood circulation and removing blood stasis, unblocking meridians and relieving pain, eliminating phlegm, softening and dispersing nodules, invigorating qi and promoting qi circulation, and soothing the liver and harmonizing the stomach. The invention also discloses a preparation method of the pharmaceutical composition.

The invention belongs to the technical field of experimental zoology, and particularly relates to a gastric cancer precancerous lesion animal model and a construction method and application thereof. The construction method of the gastric precancerous lesion animal model comprises the following steps that a modeling animal freely drinks a modeling agent solution every day for modeling, and the concentration of the modeling agent solution is increased in a gradient mode within 200 mg / L-800 mg / L along with the modeling time. The gastric cancer precancerous lesion animal model is constructed by the method. The gastric precancerous lesion animal model is applied to screening, research and development of traditional Chinese medicines for treating gastric precancerous lesions including chronic atrophic gastritis, intestinal metaplasia and dysplasia. The method can solve the technical problem that the existing gastric precancerous lesion animal model construction method cannot accurately simulate the disease stage evolution, can simply, conveniently and efficiently construct the gastric precancerous lesion model, and has important meanings for scientific research verification, drug research and development, quality control, clinical application and the like of traditional Chinese medicines or formulae for treating gastric precancerous lesions.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method and application thereof. According to the technical scheme, the traditional Chinese medicine composition is characterized by being prepared from, by weight, 10-50 parts of radix codonopsis, 5-20 parts of roasted rhizoma atractylodis macrocephalae, 5-10 parts of rhizoma pinellinae praeparata, 2-8 parts of rhizoma coptidis, 8-40 parts of poria cocos, 5-15 parts of radix salviae miltiorrhizae, 3-6 parts of rhizoma zingiberis, 5-15 parts of rhizoma cyperi, 1-20 parts of radix actinidiae chinensis and 1-5 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition provided by the invention can improve the pathological morphology of stomach tissues, increase the expression of PG I and the ratio of PG I to PG II, reduce the level of inflammatory factors and improve the atrophy degree of gastric mucosa, and is used for treating stomachache, distention and fullness, anorexia, gastric noisy and other symptoms caused by spleen and stomach qi deficiency, qi stagnation and blood stasis and damp-toxin interjunction of patients with chronic atrophic gastritis.

The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of radix codonopsis, 10 to 20 parts of rhizoma atractylodis macrocephalae, 10 to 15 parts of poria cocos, 10 to 12 parts of pericarpium citri reticulatae, 6 to 10 parts of rhizoma pinellinae praeparata, 10 to 12 parts of radix aucklandiae, 10 to 12 parts of rhizoma corydalis, 3 to 6 parts of radix notoginseng, 10 to 12 parts of fructus aurantii immaturus, 10 to 20 parts of radix ginseng rubra, 15 to 30 parts of herba hedyotidis diffusae, 15 to 30 parts of semen coicis, 10 to 15 parts of rhizoma curcumae, 10 to 20 parts of radix salviae miltiorrhizae, 10 to 20 parts of radix astragali seu hedysari and 3 to 6 parts of liquorice root. The invention further discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at chronic atrophic gastritis with pathological characteristics of gastric mucosa dysplasia and intestinal metaplasia, and is remarkable in curative effect and small in side effect through reasonable medicine compatibility.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The utility model relates to the technical field of medical apparatus and instruments, in particular to a detection sampling device for atrophic gastritis, which comprises a sleeve and a sampling component, an arc-shaped plate is connected to the outer side of the sleeve in a hot melting manner, a metal hose is fixedly connected to the bottom of the arc-shaped plate through a bolt, a connecting rod is sleeved at the top end of the sleeve, and the sampling component is connected with the connecting rod. A steel wire is fixed at the bottom end of the connecting rod through a bolt; a sampling assembly is arranged at one end of the metal hose and comprises an arc-shaped umbrella cover welded to one end of the steel wire and a column sleeve welded to one end of the metal hose, and grooves are formed in the outer side of the column sleeve at equal intervals; after the sampling assembly is inserted into the stomach of a patient, the rotating column sleeve makes contact with the interior of the stomach, so that gastric mucosa fluid makes contact with and adheres to the interior of the groove, the gastric mucosa fluid is sampled, the arc-shaped umbrella cover is pulled through the steel wire, the arc-shaped umbrella cover moves to scrape gastric mucosa tissue, and the gastric mucosa tissue is sampled.

The invention discloses a new application of Renqingchangjue and an extract of Renqingchangjue. Specifically, the invention provides a new application of Tibetan medicine Renqingchangjue and an extract in preparation of a medicine for treating chronic atrophic gastritis, and systematically clarifies an exact molecular mechanism of the Tibetan medicine Renqingchangjue for treating CAG. The core of the invention is to reveal the core signal axis of Renqingchangjue by inhibiting TNF / NF-kB / Caspase-3 for the first time, so that the Renqingchangjue synergistically exerts the effects of resisting inflammation, resisting apoptosis and promoting mucosa repair, and provides a new intervention target and scientific basis for reversing gastric mucosa gland atrophy. The invention not only provides a modern pharmacological basis for the clinical curative effect of the Renqingchangjue, but also provides a brand new technical scheme and a protection basis for developing a medicine or a medicine composition which is based on the clear pathway target and is used for treating the chronic atrophic gastritis.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition with the function of relieving stomach inflammation and a preparation method and application. The traditional Chinese medicine composition comprises a main medicine and an auxiliary medicine, the main medicine consists of cuttle bone, thunberg fritillary bulb and rheum officinale; the adjuvants comprise a first adjuvant and a second adjuvant; the first adjuvant is belladonna and daphniphyllum calycinum; the second adjuvant comprises fructus aurantii and cortex magnoliae officinalis. The traditional Chinese medicine composition provided by the invention is simple in component, only a trace amount of belladonna extract needs to be added, meanwhile, daphniphyllum calycinum is compounded, the addition of excessive other unnecessary components is avoided, and the symptom of chronic non-atrophic gastritis with erosion can be remarkably improved.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 280-320 parts of red ginseng; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 580 to 620 parts of rhizoma atractylodis macrocephalae, 280 to 320 parts of rhizoma zingiberis, 80 to 120 parts of sandalwood, 280 to 320 parts of edible tulip, 580 to 620 parts of concha arcae, 580 to 620 parts of oldenlandia diffusa, 180 to 220 parts of notholirion bulbuliferum and 280 to 320 parts of sea buckthron oil. The total effective rate of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia is 93%, and the traditional Chinese medicine composition has a remarkable clinical effect on treating chronic atrophic gastritis with intestinal metaplasia clinically.

The composition provided by the invention takes bear gall wood as a monarch drug and takes earthworm, bletilla striata, bighead atractylodes rhizome, Chinese yam and white paeony root as ministerial drugs, the earthworm and bletilla striata jointly play the effects of promoting blood circulation to remove meridian obstruction, dispersing blood stasis, removing stasis, astringing to stop bleeding and repairing injury, and the bighead atractylodes rhizome and Chinese yam are used as ministerial drugs and are used for strengthening spleen and stomach, replenishing qi and blood, providing fundamental power for the whole prescription and supporting healthy qi; liver softening, spasm relieving and pain relieving can be achieved; meanwhile, the traditional Chinese medicine composition has the effects of nourishing blood and astringing yin, can prevent other medicines in the formula from being too warm and dry or consuming yin blood, and forms dynamic and static combination compatibility with the minister medicine earthworm for promoting blood circulation to remove meridian obstruction; hairyvein agrimony, herba violae, vernonia graveolens, cuttlebone, mangnolia officinalis, semen raphani and endothelium corneum gigeriae A large number of pathological experiments prove that the traditional Chinese medicine composition can reduce stomach tissue inflammation, oxidative stress and activate apoptosis signal channels by acting on MAPK, PI3K-Akt and HIF-1 signals, so that the effect of treating chronic atrophic gastritis is achieved.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

This invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for treating chronic atrophic gastritis provided by this invention is made from the following raw materials in parts by weight: 15-25 parts of Salvia miltiorrhiza, 8-16 parts of Curcuma zedoaria (processed with vinegar), 2-6 parts of Eupolyphaga sinensis, 10-20 parts of Codonopsis pilosula, 8-16 parts of Dendrobium nobile (dried), 5-15 parts of Pinellia ternata (processed), 1-5 parts of Evodia rutaecarpa (processed), and 1-5 parts of Coptis chinensis. It has the effects of promoting blood circulation and removing blood stasis, strengthening the spleen and replenishing qi, nourishing yin and benefiting the stomach, inhibiting bacteria and inflammation, and regulating immunity. It is suitable for chronic atrophic gastritis, especially those with gastric blood stasis combined with stomach yin deficiency or spleen and stomach weakness. It can significantly repair the gastric mucosa and reverse atrophic intestinal metaplasia, and is safe and reliable, providing a new traditional Chinese medicine treatment for chronic atrophic gastritis.

The invention discloses a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition comprises the following components in parts by weight: 16-20 parts of Zhejiang radix ophiopogonis, 15-20 parts of moutan bark, 28-32 parts of salvia miltiorrhiza, 10-14 parts of pseudo-ginseng slices, 15-18 parts of curcuma zedoary, 18-22 parts of codonopsis pilosula, 28-32 parts of astragalus membranaceus and 28-32 parts of oldenlandia diffusa. The preparation method comprises the following steps: (1) cleaning the medicinal materials, and then cutting into small blocks to obtain a mixed medicinal material; (3) boiling with big fire after soaking, continuing to decoct with small fire, and filtering to obtain first medicine liquid and medicine residues; and (4) adding water again, boiling with big fire, continuously decocting with small fire, filtering to obtain a second liquid medicine, and mixing the first liquid medicine and the second liquid medicine. The traditional Chinese medicine composition can obviously improve inflammation and atrophic lesion of gastric mucosa, and has a remarkable effect on treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia.

The present application belongs to the technical field of bioinformatics, and specifically relates to a chronic atrophic gastritis biomarker screening method and system based on a multi-modal differential network. The present application comprises: preprocessing metabolome data and microbiome data, respectively constructing intra-modal interaction graphs and inter-modal interaction graphs, and obtaining a multi-modal differential network by making a difference between the interaction graphs under different clinical groupings; based on the constructed differential network, a multi-level difference evaluation index is constructed: CDI is calculated at the node level to quantify the network topology and biological function differences of the biomarkers; at the structure level, a group specificity index GSI is defined to characterize the group specificity of the differential network structure; the feature ranking results obtained by CDI and GSI are fused and screened to obtain a biomarker set for atrophic gastritis classification prediction. The present application improves the effectiveness of biomarker screening under the condition of small sample and high dimension, and provides support for subsequent targeted cultivation of candidate colonies and metabolites and development of potential intervention target points.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. Comprising the following raw materials in parts by weight: 25-35 parts of honey-fried astragalus membranaceus, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 8-10 parts of ginseng, 5-8 parts of elecampane, 2-4 parts of fructus amomi, 12-18 parts of codonopsis pilosula, 12-18 parts of poria cocos, 8-10 parts of vinegar-processed curcuma zedoary, 2-4 parts of pseudo-ginseng, 8-12 parts of oldenlandia diffusa, 10-15 parts of medlar, 8-10 parts of pericarpium citri reticulatae, 5-7 parts of ginger processed pinellia, 0.08-0.12 part of naringin and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention takes spleen invigorating and qi supplementing, qi regulating and blood activating, precise regulation and control and mucous membrane repairing as the core, specifically solves the pathogenesis of spleen deficiency and qi stagnation type CAG with deficiency in root and excess in excess, inhibits the progression of precancerous lesions, and improves the treatment effectiveness and safety.

This invention belongs to the field of gastric disease treatment, specifically relating to a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and its preparation method. The traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia comprises the following raw materials in parts by weight: Agrimonia pilosa 10-15 parts, Cyperus rotundus 8-10 parts, Scutellaria barbata 10-15 parts, Lobelia chinensis 10-15 parts, Patrinia scabiosaefolia 13-17 parts, Scutellaria baicalensis 7-11 parts, Hedyotis diffusa 10-15 parts, Prunella vulgaris 10-15 parts, Hedyotis diffusa 5-7 parts, Perilla frutescens 8-10 parts, Coptis chinensis 5-7 parts, Angelica sinensis 5-7 parts, etc. This invention focuses on the core pathogenesis of damp-heat in the spleen and stomach and stagnation of gastric collaterals. The Chinese herbal composition has the effects of clearing heat and removing dampness, regulating qi and harmonizing the stomach, nourishing blood and unblocking collaterals. Clinically, it can significantly improve the OLGA / OLGIM stage of patients with chronic atrophic gastritis with intestinal metaplasia, with a total effective rate of 65.1%, providing a safe and effective Chinese medicine solution for precancerous lesions of the stomach.

The invention provides application of a biomarker in preparation of a product for predicting damp-heat syndrome of chronic atrophic gastritis, and the biomarker comprises TM7x bacteria, and further comprises at least one of kiwifruit bacteria, actinomycetes, twin coccus and phenylacetic acid. Compared with traditional gastroscopy, the tongue coating biomarker obtained by screening through a bioinformatics method provides a non-invasive diagnosis method, so that the compliance of a patient is improved. According to the method, the medical cost is reduced, the diagnosis feasibility and accuracy are improved, and the method not only can be used for diagnosing the chronic atrophic gastritis damp-heat syndrome, but also can be popularized to early screening and prevention.

The invention belongs to the technical field of biomedical materials, and discloses a molecular probe for detecting senile chronic atrophic gastritis and application of the molecular probe. The molecular probe is coupled Mcemp1 magnetic-optical bimodal composite nanoparticles; the preparation method comprises the following steps: preparing a Fe3O4 (at) OA solution by taking ferric acetylacetonate, oleylamine and dibenzyl ether as raw materials, modifying the Fe3O4 (at) OA solution through an SPE-PEG2000-NH2 polymer, and purifying the Fe3O4 (at) OA solution to obtain a magnetic core Fe3O4-PEG-NH2 NPs; the preparation method comprises the following steps: coupling a magnetic core with Mcomp1, and then purifying, so as to obtain Fe3O4-PEG-Mcomp1 NPs (N < 3 > O34-PEG-Mcomp1); and then carrying out near-infrared fluorescent dye ICG labeling, and dialyzing to obtain the magnetic-optical dual-mode composite nanoparticles coupled with the Memp1. Non-invasive continuous monitoring is achieved through the intravenous administration magnetic particle probe, the bimodal technology is combined, gland density is quantified in real time, the gastric mucosa condition is dynamically tracked, the problems that a fluorescent probe is insufficient in penetration depth and low in quantification precision are solved, and the technical blank of dynamic evaluation and canceration early warning is filled up.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

This invention discloses a traditional Chinese medicine drug for treating atrophic gastritis and its preparation method. The drug is composed of herbs including Salvia miltiorrhiza, chicken gizzard lining, Aucklandia lappa, Amomum villosum, Taraxacum mongolicum, Shenqu (medicated leaven), Citrus aurantium, Corydalis yanhusuo, Coix lacryma-jobi, Viola yedoensis, Angelica sinensis, and Astragalus membranaceus. In preparation, about half of the herbal mixture is pulverized into a fine powder for later use; the remaining herbs are decocted twice with water, and the filtrate is concentrated into a thick paste using vacuum low-temperature concentration technology. The thick paste is mixed with the fine herbal powder, ethanol is added, and wet microcapsules are prepared using an extrusion and spheronization method. The wet microcapsules are finally dried in stages using a fluidized bed and polished to obtain the finished product. This method, by combining extraction with the use of raw powder, and employing key processes such as low-temperature concentration and staged drying, can maximize the retention of water-soluble and heat-sensitive volatile components in the herbs, significantly improving the drug's dissolution rate, active ingredient content, and long-term storage stability, thereby more effectively exerting its comprehensive therapeutic effects of invigorating the spleen and replenishing qi, promoting blood circulation and removing blood stasis, and relieving pain.

The invention specifically discloses a nine-ingredient bacon formula for treating chronic atrophic gastritis as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The nine-ingredient Bayuan prescription provided by the invention is designed for the core pathogenesis of spleen and stomach weakness and qi and blood disharmony of CAG, and has the effects of strengthening the spleen and stomach, consolidating the root and Bayuan, and regulating qi to alleviate pain.

The invention discloses an atrophic gastritis traditional Chinese medicine treatment data processing method and system based on data mining, and relates to the technical field of chronic disease data processing. The atrophic gastritis traditional Chinese medicine treatment data processing method based on data mining comprises the following steps: acquiring CT scanning data; acquiring traditional Chinese medicine treatment data; obtaining traditional Chinese medicine proportioning accuracy; and classifying and feeding back. The CT scanning image of the to-be-treated patient in the preset time period is obtained to obtain the CT scanning data and convert the CT scanning data into the text data, meanwhile, the traditional Chinese medicine treatment data of the to-be-treated patient is obtained, and then the text data and the traditional Chinese medicine treatment data are input into the traditional Chinese medicine proportioning model to obtain the traditional Chinese medicine proportioning accuracy. Finally, the to-be-treated patients are classified and fed back in combination with the obtained traditional Chinese medicine matching accuracy, the effect of improving the traditional Chinese medicine matching accuracy during atrophic gastritis treatment is achieved, and the problem that in the prior art, the traditional Chinese medicine matching accuracy and CT scanning data are not sufficiently associated during atrophic gastritis treatment is solved.

The invention discloses a traditional Chinese medicine composition for treating atrophic gastritis precancerous lesions and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: radix astragali, fructus mume, cortex cinnamomi, rhizoma curcumae, raw endothelium corneum gigeriae galli, rhizoma coptidis and radix glycyrrhizae preparata. The traditional Chinese medicine composition is remarkable in curative effect, has advantages in the aspects of gastric mucosa pathology improvement, endoscopic scoring, clinical symptoms and syndromes compared with a Chinese patent medicine Weifuchun capsule which is commonly used for treating atrophic gastritis precancerous lesions clinically, does not have obvious adverse reaction, and is good in safety.

The invention discloses a female vaginal sensitivity regulator based on stem cells and a preparation method thereof, and belongs to the technical field of biology, the female vaginal sensitivity regulator comprises mesenchymal stem cells, tomaroside A, glycerol, a scutellaria baicalensis extract and a stem cell carrier, and a vaginal injection ointment is obtained by uniformly mixing the mesenchymal stem cells, the tomaroside A, the glycerol, the scutellaria baicalensis extract and the stem cell carrier through a proper amount of deionized water. The mesenchymal stem cells added in the application can be colonized in the vaginal epithelium and vaginal environment to promote differentiation into functional cells and secrete EGF, VEGF and other regenerative factors, collagen synthesis and angiogenesis are further promoted, the thickness of atrophic mucosa is increased, glycogen secretion and lactic acid bacteria microecology are recovered, the pH acid environment is maintained, and the problem of dryness is solved. Through the synergistic effect of the tomato steroid glycoside A and the radix scutellariae extract, the differentiation expression of the mesenchymal stem cells can be promoted while local inflammatory factors are inhibited. The low-molecular-weight lycium barbarum polysaccharide provides osmotic pressure protection, so that the survival rate of stem cells is

The present invention relates to the field of small molecule drug technology, and more specifically to a drug for ameliorating chronic atrophic gastritis and its use. One object of the present invention is to provide a compound, a pharmaceutical composition comprising the compound, and its use. The 9- and 13-substituted berberine derivatives of the present invention have a significant ameliorative effect on CAG. Further studies and observations have shown that the compounds inhibit CAG symptoms, such as atrophy of gastric mucosal glandular epithelial cells, thinning of the gastric mucosa, infiltration and adhesion of large numbers of neutrophils and lymphocytes, and inflammatory factors. It was found that the 9- and 13-substituted berberine derivatives of the present invention can be used to prevent and / or treat CAG.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.

The invention discloses a construction method of a chronic atrophic gastritis precancerous lesion animal model, and the construction method comprises the following specific steps: selecting experimental mice, randomly and averagely dividing the experimental mice into a model group and a blank control group, the experimental mice of the model group drink an MNU solution I by themselves and use an MNU solution II for intragastric administration once a week, and the blank control group normally diets; after modeling, dissecting and taking stomach tissues for later use; the MNU solution I is an N-nitroso-N-methylurea solution with the concentration of 290 mg / L to 310 mg / L; the MNU solution II is an N-nitroso-N-methylurea solution with the concentration of 1.6 g / L to 1.7 g / L; according to the method, 14-week modeling can be achieved, intestinal metaplasia, heterodysplasia and even a small number of cancer cells can occur in 14 weeks, and compared with a traditional MNNG combined multi-factor modeling method, the modeling method has the advantages that the modeling method is simplified, experimental errors and individual differences are reduced, the modeling period is shortened, and the modeling success rate is increased.

The invention discloses a traditional Chinese medicine composition for treating atrophic gastritis and a preparation method of the traditional Chinese medicine composition for treating atrophic gastritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-10 parts of angelica sinensis, 3-10 parts of ligusticum wallichii, 10-30 parts of radix paeoniae alba, 5-20 parts of dandelion, 10-30 parts of herba ecliptae, 5-20 parts of sculellaria barbata, 5-20 parts of semen litchi, 5-20 parts of fructus aurantii, 10-30 parts of lily, 5-20 parts of mangnolia officinalis, 5-20 parts of radices trichosanthis, 10-30 parts of oriental wormwood, 3-10 parts of endothelium corneum gigeriae galli, 10-30 parts of oldenlandia diffusa, 10-30 parts of honeysuckle and 2-10 parts of liquorice. The traditional Chinese medicine composition can well treat atrophic gastritis, and is remarkable in effect, safe and reliable.

The invention discloses an application of N-[3-chloro-4-({[2-(methylamino)-6-(2-pyridyl)-4-pyrimidinyl] amino} methyl) phenyl] in treating chronic atrophic gastritis, which is mainly used for recovering blood supply of gastric mucosa, accelerating repair after gastric mucosa injury and maintaining the function of gastric mucosa barrier by relaxing arteries under gastric mucosa, and has the advantages of being capable of treating chronic atrophic gastritis, and capable of treating chronic atrophic gastritis. The N-[3-chloro-4-({[2-(methylamino)-6-(2-pyridyl)-4-pyrimidinyl] amino} methyl) phenyl] has the advantages that the effective treatment effect is achieved, a new thought is provided for the treatment of chronic atrophic gastritis, and a new application of the N-[3-chloro-4-({[2-(methylamino)-6-(2-pyridyl)-4-pyrimidinyl] amino} methyl) phenyl] medicine for treating chronic atrophic gastritis is also provided.